Trinity Life Sciences Offers Learnings to Biopharma Companies on How to Redesign Their Go-To Conference Strategy and Plan Budget Allocation in a Virtual World

New White Paper Entitled “Navigating the New World of Virtual Conferences, The Example of ASCO 2021” Now Available

WALTHAM, Mass.--(BUSINESS WIRE)--Trinity Life Sciences, a leader in global life sciences commercialization solutions, is offering learnings to the biopharma industry on how to redesign their go-to conference strategy and plan budget allocation as conferences continue to be offered in a virtual or hybrid format. Trinity conducted a post-conference survey of 100 U.S. oncologists about their experience at the ASCO 2021 Virtual Conference and published the findings in a new white paper entitled Navigating the New World of Virtual Conferences, The Example of ASCO 2021.

Almost all oncologists surveyed, 85 percent, attended at least one conference virtually during the COVID-19 pandemic, and only 9 percent attended in person. Looking ahead, conferences will likely be hybrid in nature: roughly half of respondents plan to attend virtually, while the rest said they would attend in person.

From the survey, three main areas were explored in the white paper:

1. Overall perceptions of virtual ASCO
2. Top-performing manufacturers
3. Outlook for stakeholder engagement at medical conferences

One of the main drawbacks noted at virtual ASCO was the lack of impromptu in-person networking opportunities. Conferences are often the only place oncologists can meet and build relationships with peers. Back-and-forth discussion and debate on different treatment approaches or promising research directions can be stimulated by a presentation or a poster session. Moderator-controlled chat boxes lose much of that dialogue. Some felt technology platforms were not as intuitive, and experienced difficulties navigating between online events.

“To be effective, a virtual environment will need to be designed from the ground up, rather than be based on a physical convention center,” said Andy Wong, Partner, Trinity Life Sciences. “Immersion, superior editing and greater interactivity will need to face the shorter attention spans of virtual interaction. Accomplishing this will take more resources, time and effort than is generally appreciated. Constant reevaluation of effectiveness will be necessary.”

Media interested in obtaining the white paper can contact Elizabeth Marshall, [e-mail].

About Trinity Life Sciences

Trinity Life Sciences is a trusted strategic commercialization partner, providing evidence-based solutions for the life sciences. With 25 years of experience, Trinity is committed to solving clients’ most challenging problems through exceptional levels of service, powerful tools, and data-driven insights. Trinity’s range of products and solutions includes industry-leading benchmarking solutions, powered by TGaS Advisors. To learn more about how Trinity is elevating life sciences and driving evidence to action, visit trinitylifesciences.com.